CTLA-4 MONOCLONAL ANTIBODY LICENSE AGREEMENTLicense Agreement • October 1st, 2021 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 1st, 2021 Company Industry JurisdictionIn consideration of the mutual promises and conditions set forth herein and other good and valuable consideration, WuXi and Akriveia, intending to be legally bound, agree as follows:
CTLA-4 MONOCLONAL ANTIBODY LICENSE AGREEMENTLicense Agreement • May 24th, 2021 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 24th, 2021 Company Industry JurisdictionIn consideration of the mutual promises and conditions set forth herein and other good and valuable consideration, WuXi and Akriveia, intending to be legally bound, agree as follows: